Meta10-BCMA

N/A

Report date: 2025/07/29 20:00:11

Base Information

Drug NameMeta10-BCMA
Drug Alias NameMetabolically Armed BCMA CAR-T Cells therapy (Anhui Provincial Hospital)Meta10-BCMA
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulatorsT lymphocyte replacements
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaImmunoglobulin Light-chain AmyloidosisLeukemia, Plasma Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAnhui Provincial Hospital
China Registration ClassN/A

Develop Information

Active CompaniesAnhui Provincial Hospital
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaImmunoglobulin Light-chain AmyloidosisLeukemia, Plasma Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A